KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Merck (MRK) Interest Coverage Ratio (2011 - 2013)

Merck (MRK) reported Interest Coverage Ratio of 13.09 for Q1 2013, down 49.75% year-over-year from 26.05 in Q1 2012, and up 11.98% on a QoQ basis from 14.87 in Q4 2012.

Merck (MRK) has 3 years of Interest Coverage Ratio data on file, last reported at 13.09 in Q1 2013.

  • Quarterly Interest Coverage Ratio fell 49.75% year-over-year to 13.09 in Q1 2013, while the trailing twelve-month figure through Dec 2013 was 62.01 (down 475.24% YoY) and the FY2012 annual result came in at 4.28, up 16.0% from the prior year.
  • Interest Coverage Ratio rose to 13.09 in Q1 2013 per MRK's latest filing, from 14.87 in the prior quarter.
  • Across five years, Interest Coverage Ratio topped out at 8.33 in Q2 2012 and bottomed at 15.36 in Q2 2011.
  • The 3-year median for Interest Coverage Ratio is 12.53 (2011), against an average of 12.23.
  • The widest annual swing landed in 2012, when Interest Coverage Ratio surged 45.81%; it then slumped 49.75% in 2013.
  • Tracing MRK's Interest Coverage Ratio over 3 years: stood at 15.0 in 2011, then gained by 0.84% to 14.87 in 2012, then rose by 11.98% to 13.09 in 2013.
  • Per Business Quant, the three latest MRK Interest Coverage Ratio figures stand at 13.09 (Q1 2013), 14.87 (Q4 2012), and 10.78 (Q3 2012).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Interest Cover (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn -
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 23.39
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 4.06
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 10.78
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn -
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2013 -13.09
Dec 31, 2012 -14.87
Sep 30, 2012 -10.78
Jun 30, 2012 -8.33
Mar 31, 2012 -8.74
Dec 31, 2011 -15.00
Sep 30, 2011 -11.36
Jun 30, 2011 -15.36
Mar 31, 2011 -12.53